FILTER

FILTERED INTERVIEW RESULTS

Joseph Kemp

VICE PRESIDENT AND GENERAL MANAGER - BALD MOUNTAIN, KINROSS GOLD CORPORATION

"Interestingly, despite increasingly challenging operating environments, the industry’s ounce production continues to maintain or improve. That speaks to the creativeness and technical expertise of the whole value chain of the industry."

United States

Pharma & Life Sciences

Andrea Confetti & Roberto Fanelli

EXCLUSIVE SYNTHESIS BUSINESS UNIT LEADER (AC) & CATALOGUE APIS BU DEPUTY MANAGER (RF), DIPHARMA FRANCIS

RF: "Our experience in developing proprietary chemical processes and alternative solutions to support the generic API industry has been instrumental in rapidly expanding our CDMO activities."

United States

Pharma & Life Sciences

Daniel Palmacci

PRESIDENT, CELL & GENE DIVISION, LONZA

"We want to give patients the best access to the amazing technology and treatments being developed by cell and gene therapy innovators. This is the modality with the greatest potential in the healthcare industry today."

United States

Pharma & Life Sciences

John Patrick Oroho

PRESIDENT AND GENERAL MANAGER, PORZIO LIFE SCIENCES

"We are always looking at new regulations in the US and worldwide: laws very seldom change incrementally, so we adapt our systems to reflect that."

United States

Pharma & Life Sciences

Michael Quirmbach

CEO AND PRESIDENT, CORDENPHARMA

"Our main mission is the execution of a >€200 million investment into CapEx projects that will bring additional capacity and technologies online to support pharma and biotech customers as their drug development projects progress."

United States

Pharma & Life Sciences

Christiana Bardon

CO-MANAGING PARTNER, MPM | BIOIMPACT CAPITAL

"We see this as an exciting time to be investing in record-high levels of innovation at very attractive valuations."

United States

Pharma & Life Sciences

Debbie Hart

PRESIDENT AND CEO, BIONJ

"To ensure that New Jersey maintains this leadership position, BioNJ will continue to work with State government to support industry and stave off onerous proposals. "

United States

Pharma & Life Sciences

Jay Shukla

PRESIDENT AND CEO, NIVAGEN PHARMACEUTICALS, INC.

"Our partners benefit from our market intelligence and cost-splitting, and we attain the manufacturing capability and resources. We will continue to grow our partnership model now that we are expecting to double our revenue."

United States

Pharma & Life Sciences

Robert Poe

CEO, OLON RICERCA BIOSCIENCES

"What we are doing here is beginning the build-out of a high-potency API suite, so that we can get up to a few hundred grams made for early studies and transfer those processes to our sites in Italy for the clinical trial phase."

United States

Pharma & Life Sciences

Manni Kantipudi & Ramesh Subramanian

CHIEF EXECUTIVE OFFICER (MK) & CHIEF COMMERCIAL OFFICER (RS), ARAGEN LIFE SCIENCES

"Overall, I believe the virtual biotech model is here to stay and companies will increasingly look at CRO/CDMO companies for assistance in taking drugs from discovery to commercialization."